(Q38209147)

31 August 2017

title

The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status (English)

1 reference

31 August 2017

1 reference

angiogenesis inhibitor

1 reference

1 reference

Pilar García-Alfonso

1

1 reference

31 August 2017

Enrique Grande

2

1 reference

31 August 2017

Eduardo Polo

3

1 reference

31 August 2017

Ruth Afonso

4

1 reference

31 August 2017

Juan José Reina

5

1 reference

31 August 2017

Mónica Jorge

6

1 reference

31 August 2017

Juan Manuel Campos

7

1 reference

31 August 2017

Virginia Martínez

8

1 reference

31 August 2017

Cristina Angeles

9

1 reference

31 August 2017

Clara Montagut

10

1 reference

31 August 2017

publication date

3 May 2014

1 reference

31 August 2017

1 reference

31 August 2017

volume

17

1 reference

31 August 2017

issue

4

1 reference

31 August 2017

page(s)

805-821

1 reference

https://scigraph.springernature.com/pub.10.1007/s10456-014-9433-6

31 August 2017

exact match

0 references

cites work

The consensus coding sequences of human breast and colorectal cancers

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

The genomic landscapes of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Effect of p53 status on tumor response to antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Integrated molecular dissection of the epidermal growth factor receptor (EGFR) [corrected] oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Phase 1 study of aflibercept administered subcutaneously to patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Phase II trial and pharmacokinetic study of thalidomide in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

The combination of capecitabine and thalidomide in previously treated, refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Biomarkers to predict the clinical efficacy of bevacizumab in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Biomarkers of response and resistance to antiangiogenic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Assessing the in vivo efficacy of biologic antiangiogenic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10456-014-9433-6

10.1007/S10456-014-9433-6

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference